Os 166 melhores médicos do mundo para o tratamento de cancro da tiroide

O Dr. Irfan Cicin é professor de Oncologia Médica no Hospital İstinye University Liv Topkapı. Especializa-se no tratamento de cancros complexos, incluindo glioblastoma, cancro do pulmão e tumores pancreáticos. É professor na Faculdade de Medicina da Universidade de Trakya. O Dr. Cicin serviu anteriormente como médico na Força Aérea Turca.

• Realiza terapias sistémicas como imunoterapia, quimioterapia e terapia hormonal.
• Trata uma vasta gama de condições, incluindo casos ginecológicos, ortopédicos e neuro-oncológicos.
• Especialista em HIPEC e quimioembolização para neoplasias hepáticas e abdominais.
• Trabalha num hospital universitário de 300 camas com 33 departamentos médicos.

O Dr. Lee Jihyeon é cirurgião de mama e tireoide. Possui experiência em doenças mamárias benignas e malignas, cirurgia oncoplástica de mama e biópsia Mammotome. Também trata doenças da tireoide e paratireoide. Pratica cuidados intensivos pulmonares (medicina de cuidados críticos).

Obteve seu diploma de medicina na Faculdade de Medicina da Universidade Yonsei. Concluiu um estágio e uma residência em cirurgia geral no Hospital Severance da Universidade Yonsei. Também realizou uma bolsa de curta duração no Hospital do Instituto do Câncer do JFCR, no Japão.

Seus cargos anteriores incluem Chefe de Cirurgia no Hospital Cristão de Incheon e Cirurgião Assistente no Hospital Geral Cheil. Atuou como Diretor do Centro de Mama e como Presidente e Chefe de Cirurgia no Hospital Samsung Cheil. Foi Presidente de Cirurgia e Vice-Presidente de Assuntos Médicos no Hospital Geral Cheil. Também atuou como Professor Clínico de Cirurgia no Hospital Gangnam CHA, Universidade CHA.

O Professor Zheng Qiu Hong é Diretor do Centro de Pesquisa em Terapia Celular e um especialista nacional sênior em bioterapia. Ele é professor e supervisor de mestrado na Universidade Médica de Fujian. Possui mais de 30 anos de experiência clínica em biologia molecular tumoral e bioterapia. De 2012 a 2013, foi pesquisador visitante em pesquisa com células-tronco na Escola de Ciências da Vida da Universidade de Connecticut. Anteriormente, ocupou cargos de liderança no Hospital de Câncer de Fujian, incluindo diretor do Laboratório de Biologia Molecular Tumoral e diretor do Laboratório de Pesquisa em Oncologia Cirúrgica. Também atuou como vice-diretor do Laboratório Chave de Bioterapia Tumoral de Fujian e vice-diretor do Centro de Bioterapia e Imunoterapia.

Suas nomeações incluem ser membro do Comitê Permanente do Comitê de Bioterapia da Associação Chinesa de Hospitais de Pesquisa. Ele também é membro do Comitê de Imunologia Tumoral e Bioterapia da Sociedade Chinesa de Imunologia. Além disso, é vice-presidente do Comitê Acadêmico do Centro de Pesquisa em Terapia Celular de Xiamen no Primeiro Hospital Afiliado da Universidade de Xiamen.

O Dr. Elkhan Mammadov é oncologista clínico. Concentra-se no diagnóstico e tratamento do cancro, incluindo quimioterapia citotóxica, hormonoterapia, terapia direcionada (fármacos inteligentes) e imunoterapia.

Educação: Universidade Médica do Azerbaijão, MD (2004–2010). Universidade de Istambul, Faculdade de Medicina de Istambul, formação em Medicina Interna (2014–2019). Hospital Universitário Istanbul Medipol Mega, formação de subespecialidade em Oncologia Clínica (2019–2022).

Experiência: 5 anos em Medicina Interna. 3 anos em Oncologia Clínica.

Afiliações: Sociedade Turca de Oncologia Clínica. ESMO (Sociedade Europeia de Oncologia Clínica). ASCO (Sociedade Americana de Oncologia Clínica).

Li Guiyuan, MD, is Chief Physician in the Department of Medical Oncology at Shanghai Tongji Hospital. He has practiced oncology since 1996 and has more than 20 years of experience. He earned a master’s degree in Oncology from Nanjing University in 2003. He has worked in the hospital’s Oncology Department since then.

His clinical work includes chemotherapy for lung, breast, ovarian, and gastrointestinal cancers. He also provides targeted and anti‑angiogenic therapies for malignant tumours. He manages malignant pleural and peritoneal effusions and bone metastases with multimodal care, including immunotherapy.

He has authored more than 10 basic and clinical papers, including “Tumour Hypoxia and Its Therapeutic Strategies” and “Establishment of Tumour Model with B16 Melanoma Cell Line of C57BL/6 Mice in ICR Mice.” He received the Medical Achievement Award from the General Logistics Department of the PLA for “Research and Application of Early‑diagnosis and Prediction Model for Metastasis of Non‑small‑cell Lung Cancer.” He co‑authored “Evidence‑based Oncology Treatment” and “Handbook of Modern Evidence‑based Diagnosis and Treatment of Cancer.” He has also taken part in key projects of the National Natural Science Foundation of China.

Dr. Wan‑Sung Kim, MD, PhD, is Director of the Thyroid Center and an Associate Professor of Surgery at Myongji Hospital, an educational partner of Hanyang University. He is a breast and thyroid surgeon. He treats cancer and benign disease and focuses on minimally invasive thyroid and adrenal surgery.

Expertise: endoscopic and robotic thyroidectomy (transoral, axillary-areolar), thyroid radiofrequency ablation, ethanol ablation for thyroid lesions, and endoscopic or robotic adrenal tumor surgery.

He previously served as Head of Surgery at Myongji Hospital and Chuncheon Gangnam Hospital. He completed his residency and a breast and thyroid fellowship at Myongji. He holds an MD and MS from Catholic Kwandong University and a PhD from Kangwon National University. He is a member of the Korean Association of Thyroid and Endocrine Surgeons, the Korean Breast Cancer Society, the Korean Surgical Society, and the Korean Surgical Ultrasound Society.

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

O Dr. Raanan Berger é o diretor do Centro de Câncer do Sheba Medical Center. Ele foi incluído na lista de "Melhores Médicos" da Forbes Israel em 2025. O Dr. Berger é especializado em oncologia geniturinária e trata tumores complexos de próstata com radioterapia. Ele completou um pós-doutorado no Dana-Farber/Harvard Cancer Institute.

• Chefia a unidade de pesquisa clínica focada em oncologia molecular.
• Coautor de mais de 20 artigos revisados por pares sobre câncer de próstata e mutações BRCA.
• Membro da Sociedade Americana de Oncologia Clínica (ASCO).
• Realiza terapia sistêmica e radioterapia em um hospital classificado entre os 10 melhores do mundo.

Assoc. Prof. Priv.-Doz. Dr. Alexander W. Hauswirth is a specialist in internal medicine and haemato‑oncology at JUVENIS. Since 2010, he has served as the lead senior physician for Haematology/Haemostaseology and Oncology at the Clinic for Internal Medicine I, Medical University of Vienna/AKH Vienna, Austria’s largest hospital.

He earned his medical degree from the University of Vienna in 1999. He received the venia docendi in 2010 and was appointed Associate Professor in 2012. He completed an additional haemato‑oncology qualification in 2014. As a Schrödinger Fellow in Salamanca in 2009–2010, he researched CLL stem and precursor cells. He has published regularly since 2000.

Accreditations include Austrian Medical Chamber diplomas in emergency medicine (since 2009) and sports medicine (2018). Awards include the Schrödinger Fellowship (2009), the ÖGHO award (2009), and the European Society of Chemotherapy poster award (2003). Clinical focus: anaemias, leukaemias, lymph node disorders, clotting and anticoagulation, and pre‑operative clearance. Languages: German and English.

Avi Hefetz é um especialista líder no diagnóstico e tratamento cirúrgico de oncologia de cabeça e pescoço no Centro Médico Assuta – a maior clínica médica de Israel para esta especialidade.

• Chefia o departamento de cirurgia e o departamento de oncologia de cabeça e pescoço
• Membro da Academia Americana de Otorrinolaringologia – Cirurgia de Cabeça e Pescoço
• Também é membro da Sociedade Israelense de Otorrinolaringologia e da Sociedade Americana de Cabeça e Pescoço
• Ex-cirurgião sênior de cabeça e pescoço em Tel Aviv e cofundador do Centro ARAM

O Professor Kluger é especialista em oncocirurgia no Centro Médico Rambam.

• Especialista sênior com décadas de experiência em cirurgia de câncer de tireoide
• Realiza operações oncológicas especializadas
• Lidera e ensina em uma instituição médica de alto nível
• Foca em planos complexos de tratamento de câncer

O Dr. Karatas formou-se em instituições internacionais de renome, incluindo a Universidade Estadual de Ohio e a Escola de Medicina de Hannover, especializando-se em cirurgia de cabeça e pescoço.

• Especialista em otorrinolaringologia e cirurgia de cabeça e pescoço
• Membro da Academia Americana de Otorrinolaringologia e Cirurgia de Cabeça e Pescoço
• Formação extensa em otologia e neuro-otologia
• Membro da Associação Turca de Otorrinolaringologia e Cirurgia de Cabeça e Pescoço

Professor de Otorrinolaringologia – O Dr. Son é especializado em oncologia ORL no Samsung Medical Center.

• Especialista no diagnóstico e tratamento do cancro da tiroide
• Foca-se em cancros relacionados com a ORL
• Trabalha num centro médico de referência na Coreia do Sul

O médico é um especialista experiente em radiologia intervencionista, com um foco clínico dedicado à imagiologia e intervenções da tiroide e da próstata. Com uma base académica sólida da Faculdade de Medicina da Universidade de Istambul Cerrahpaşa e uma formação de residência especializada em radiologia no Hospital de Formação e Investigação S.B. Haydarpaşa Numune, o médico traz uma vasta experiência para a área.

Ao longo de uma carreira distinta, o médico contribuiu para a prática clínica em instituições como o Hospital da Universidade Başkent de Istambul e o Hospital de Formação e Investigação S.B. Haydarpaşa Numune. Além disso, o médico possui formação em gestão de saúde pela Universidade de Anadolu e mantém membros profissionais ativos na Câmara Médica de Istambul e na Sociedade de Radiologia de Istambul.

Chefe do Departamento de Cirurgia de Cabeça e Pescoço no Samsung Medical Center – o Dr. Baek é especializado em tratamentos de câncer de tireoide.

• Otorrinolaringologista com vasta experiência em cirurgias de cabeça e pescoço
• Lidera uma equipe especializada em casos de câncer de tireoide
• Trabalha em um dos principais centros médicos da Coreia do Sul

Especialista em cirurgia de câncer de tireoide nos hospitais Büyük Anadolu, com experiência em vários campos da oncologia cirúrgica.

• Realiza cirurgias oncológicas, incluindo pâncreas, ductos biliares e mama
• Experiente em cirurgia oncológica para cânceres de estômago e cólon
• Também se especializa em cirurgia metabólica bariátrica e cirurgia de diabetes

O Dr. Popovcer especializa-se em cancro da tiroide com formação avançada em radiocirurgia pelo Memorial Sloan Kettering Cancer Center.

• Mais de _doctor_9982_ anos de experiência em oncologia e radioterapia
• Diretor do Departamento de Oncologia do Hospital Universitário Hadassah
• Formação de subespecialidade (fellowship) em tratamento multidisciplinar do cancro na Universidade de Michigan
• Especialista em terapia biológica e imunoterapia personalizada para o cancro da tiroide

O médico é especialista em cirurgia geral com foco em doenças da tireoide e paratireoide, realizando mais de 200 cirurgias anualmente usando técnicas minimamente invasivas. Além disso, o médico é habilidoso no tratamento laparoscópico de doenças adrenais. O médico aplica ampla experiência na organização do tratamento de patologias gastrointestinais, incluindo esôfago, estômago, cólon, fígado, ductos biliares e pâncreas, bem como no tratamento de doenças da parede abdominal e doenças tumorais complexas.<\/p>

O Dr. Joseba Rebollo Liceaga traz mais de _doctor_9719_ anos de experiência em oncologia, especializando-se em cancro da tiroide no Quironsalud Torrevieja.

• Chefe de Oncologia na Clínica San Miguel de Navarra durante _doctor_9719_ anos
• Especialista em Oncologia Médica pela Clínica Universidad de Navarra
• Autor de pesquisas sobre técnicas inovadoras de eletroquimioterapia
• Membro de equipas oncológicas multidisciplinares desde 2003